甲状腺功能亢进症的药物治疗

被引：18

作者：

何婷婷

肖海鹏

机构：

[1] 中山大学附属第一医院内分泌科

来源：

国际内分泌代谢杂志 | 2011年 / 01期

关键词：

甲状腺功能亢进症; 抗甲状腺药物; 甲巯咪唑; 丙基硫氧嘧啶;

D O I：

暂无

中图分类号：

R581.1 [甲状腺机能亢进症];

学科分类号：

摘要：

抗甲状腺药物（ATD）治疗的最佳方案要从药物的选择、具体剂量、给药方式、服药疗程、是否合用左旋甲状腺素（L-T4）、免疫抑制剂及其他影响患者缓解率的因素等多方面综合考虑。除妊娠期妇女外,目前大多数学者将甲硫咪唑（MMI）列为治疗甲状腺功能亢进症（甲亢）的首选药物。药物具体起始剂量可根据患者甲状腺的大小、甲亢病情的严重程度决定,治疗持续时间为12～18个月。但也有将传统的滴定疗法作为治疗甲亢的首选。对于是否在ATD治疗过程中合用L-T4及何时加用L-T4疗效更好,目前仍有争论,而免疫抑制剂的广泛使用仍需要更多临床研究来确认其临床疗效及安全性。

引用

页码：19 / 21

共 7 条

[1]

Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy[J] . Dinesh Khanna,Kelvin K.L. Chong,Nikoo F. Afifiyan,Catherine J. Hwang,Diana K. Lee,Helene Chokron Garneau,Robert A. Goldberg,Christine H. Darwin,Terry J. Smith,Raymond S. Douglas.Ophthalmology . 2010 (1)

[2] PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells [J].

Yang, Jichun ;

Wang, Chunjiong ;

Li, Jing ;

Burkhardt, Brant R. ;

Robert-Cooperman, Claudia E. ;

Wilson, Camella ;

Gao, Zhiyong ;

Wolf, Bryan A. .

FEBS LETTERS, 2009, 583 (18) :3009-3015

[3]

Treatment of Graves' Hyperthyroidism: Evidence-Based and Emerging Modalities[J] . Laszlo Hegedüs.Endocrinology and Metabolism Clinics of North America . 2009 (2)

[4] Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease [J].

Nakamura, Hirotoshi ;

Noh, Jaeduk Yoshimura ;

Itoh, Koichi ;

Fukata, Shuji ;

Miyauchi, Akira ;

Hamada, Noboru .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (06) :2157-2162

[5]

Effects of Antithyroid Drugs on Radioiodine Treatment: Systematic Review and Meta-Analysis of Randomised Controlled Trials[J] . BMJ: British Medical Journal . 2007 (7592)

[6]

Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy[J] . Mustafa Sahin,Murat Faik Erdogan,Gurbuz Erdogan.European Journal of Internal Medicine . 2005 (5)

[7] Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells [J].

Wang, Q ;

Li, L ;

Xu, E ;

Wong, V ;

Rhodes, C ;

Brubaker, PL .

DIABETOLOGIA, 2004, 47 (03) :478-487

← 1 →